Executive Deputy Director of the Medical Health Research Center, Old Science and Technology Association, Tsinghua University
Chief Marketing Consultant (former Business President) of Jointown Pharmaceutical Group, Initiator of China Pharmaceutical Bidding Alliance, Special Lecturer for EMBA programs at Tsinghua University and Peking University, Lead Instructor for "Pharmaceutical Channel Management" at Peking University School of Medicine Continuing Education, Appointed Expert of the 2017 International Academic Committee at Guangzhou International Rehabilitation Forum, Committee Member of the Chinese Medicine Association's Drug Economics Committee. Editor-in-Chief of the Chinese Academy of Social Sciences and China Association for the Study of Drug Regulation’s “Medical Device Blue Book”; Editor-in-Chief of the “Blood Transfusion Services Blue Book”. Authored *Channel Management Is As Simple As This* and *New E-commerce: Becoming the Remaining 3%*. Chief Editor of eight volumes of *China Blood Transfusion Industry Development Report (2016-2023)*, seven volumes of *China Medical Device Industry Development Report (2017-2023)*, and one volume of *China Medical Device Industry Data Report (2019)*. Since 2001, has been tracking and participating in pharmaceutical and medical device tenders across China, and founded sales tools such as the *Internal Control System for Online Bidding of Pharmaceutical (Device) Enterprises* and the *Online Bidding Early Warning System*, which have been widely applied in the industry.
Professor at China Pharmaceutical University
Co-CEO of Haichang Biotech
Dr. Meng Xiaofeng has over 20 years of extensive experience in the pharmaceutical industry and is a highly acclaimed authority in international regulatory affairs and GMP compliance. He has substantial expertise and notable achievements in compliance management for U.S. company operations and product launches, innovative R&D of novel drug formulations, international registration of high-end pharmaceutical products, and the establishment of advanced quality systems in pharmaceutical enterprises. At Haichang Biotech, he successfully contributed to the EU approval and market launch of albumin-bound paclitaxel injectable; managed nearly 200 U.S. ANDAs through self-development and acquisitions, covering conventional formulations and controlled substances; led quality system implementations and FDA/EU on-site audits for multiple companies; and assisted nearly 10 partner companies in passing FDA inspections with outstanding results.
National GMP Inspector, Registration Verification Officer
National GMP inspector and registration verifier for pharmaceuticals, has long been engaged in drug regulation, is familiar with drug regulatory laws and on-site inspection requirements, and has provided training sessions for GMP inspectors and pharmaceutical manufacturers multiple times.
General Manager of Livzon Pharmaceutical Group Quality Management Headquarters
Chairman of the Guangdong Pharmaceutical Association's Authorized Person for Drug Production Quality Professional Committee
Senior Engineer in Pharmaceutical Engineering (Professor Level), Ph.D.
Director of the Professional Committee of Authorized Persons for Pharmaceutical Production Quality, Guangdong Pharmaceutical Association;
Director and Vice Director of the Chinese Patent Medicine Professional Committee of Guangdong Pharmaceutical Association;
Vice Chairman of the Excipients Professional Committee of Guangdong Pharmaceutical Association.
Current Professional and Academic Expertise: Pharmaceutical Engineering Technology, Research and Development of New Traditional Chinese Medicine and Production Quality Management; Establishment and Supervision of Quality Systems for Drug Production and Scientific Research; Comprehensive Management of Pharmaceutical Manufacturing Enterprises; Group-wide Quality Management;
Chief Audit Officer of Changzhou Siyao Pharmaceutical Co., Ltd.
Senior Engineer, Licensed Pharmacist, Master of Pharmaceutical Engineering, MBA. With 20 years of professional experience, responsible for quality management, product registration and release, FDA project management, ISO system deployment and implementation, supply chain auditing, etc. As a GXP expert certified by multiple associations such as ASQ and Exemplar Global, has over 10 years of supply chain audit experience in the Asia-Pacific region, conducted 500+ GMP/GCP assessment audits on APIs, excipients, formulations, medical devices, and CRO/CMO/CDMO facilities. Familiar with various dosage forms, biologics, raw materials, excipients, and medical devices.
Former Head of the National Drug Production Inspection Team
Hu Miao, Distinguished Professor of the School of Pharmaceutical Sciences, mainly engages in research on biopharmaceutical policies and industry-education integration. Hu graduated with a master's degree in Biochemical Engineering from Zhejiang University in March 2005, and began working at a provincial drug inspection agency in April 2005 for nearly two decades. Possessing qualifications as a national inspector for drug production, drug distribution, medical device operation, and provincial cosmetics inspections, Hu has led over 200 inspections in various capacities, including serving as the lead inspector for national drug production inspections since 2011. In February 2023, Hu joined a vocational undergraduate university as a faculty member.
Director of the Chemical Drug Testing Institute, Sichuan Provincial Institute for Drug Control
Liu Feng, currently the Director of the Chemical Drug Testing Institute of the Sichuan Provincial Institute for Drug Control, Chief Pharmacist, National Drug Inspector, National CNAS Accreditation System Auditor, and Sichuan Provincial GMP and Registration Inspector, among others. From October 2015 to January 2017, he worked as a drug reviewer at the Center for Drug Evaluation of the China Food and Drug Administration. His main responsibilities include testing and inspection of drugs and cosmetics, review of registration applications, and research on related quality control methods. He has won one first prize and one second prize for provincial scientific and technological progress.
Quality Director of Federal Pharmaceutical Group
Group Quality Director of Bright Future Pharmaceuticals (China) Co., Ltd. With over 40 years of experience in pharmaceutical production quality, worked successively at Sichuan Leshan Changzheng Pharmaceutical Co., Ltd. and Zhuhai Bright Future Pharmaceutical Co., Ltd. Member of the Expert Database of Guangdong Provincial Food and Drug Administration, Editorial Board Member of "China Pharmaceutical Equipment Impurities" and "Guangdong Authorized Person Magazine." Expert of Guangdong Certification and Accreditation Association.
Published "Statistical Analysis of Drug Stability" and "Statistical Analysis of Optimal Drug Mixing Time" in the *Chinese Journal of Pharmaceutical Industry*, and "Overview of API Process Validation" and "Overview of Simulated Filling for Sterile Drugs" in the *China Pharmaceutical Equipment Magazine*!
Pharmaceutical Manufacturing Systems Engineering and GMP Expert
With over 30 years of experience in pharmaceutical production and quality management, having worked in various fields and roles within pharmaceutical manufacturing. Also served as an industry representative in the revision and implementation of China's 2010 GMP regulations.
Currently engaged in in-depth exploration and practical research work in the fields of pharmaceutical production process technology, pharmaceutical engineering planning and design, pharmaceutical production and management, and GMP technology.
Quality Director of Shenzhen CR&Jiuxin Pharmaceutical Co., Ltd.
Ye Fei, a senior EU and FDA certification quality compliance expert, has served as the QA manager for EU and FDA certifications in multiple enterprises, possessing rich practical experience in regulatory and cGMP implementation. He led the EU certification work for two sterile active pharmaceutical ingredient (API) and sterile preparation facilities, with extensive experience and deep insights into sterile management. Editorial board member of *Quality and Safety Risk Control Guidelines for Pharmaceutical Production in Guangdong Province*. Member of the editorial board for the new GMP guidelines, participated in the writing and review of *Materials and QC Laboratory*, *Sterile Preparations* (Volume I), *Facilities and Equipment*, and took part in the dissemination and training on the sterile section.
Founder of Pharmaceutical Cloud Studio, renowned expert in pharmaceutical market access, marketing models, and compliance consulting
Canghe Dian, founder of the pharmaceutical cloud studio, well-known expert in pharmaceutical market access, marketing models, and compliance consulting, with nearly 20 years of practical experience in pharmaceutical marketing. In recent years, he has been dedicated to researching China's pharmaceutical policies and market strategies, observing and analyzing them with a cool head to explore the development trends and optimal business models of the pharmaceutical industry amid the new healthcare reform wave and the mobile internet era. He provides consulting services for enterprises on marketing transformation, compliance system construction, and market access projects, and offers pharmaceutical policy research references and market consultation advice to multiple securities firms and fund companies.
Successively published "Research Report on China's Drug Procurement Policies" (2015 Edition, 2015-2017 Edition, 2020 Edition/2022 Edition), "Research Report on China's Medical Consumables Procurement Policies 2022," and the monographs "The Business Logic of Pharmaceutical Marketing," "Building a New Type of Industry-Commerce Cooperation and Sustainable Development Professional Marketing Service Model in the Pharmaceutical Industry," and "Business Insights Under the Background of Prescription Outflow," with over a hundred articles published in mainstream pharmaceutical professional media.
General Manager of Shenzhen Aoqi Biomedical Co., Ltd.
General Manager of Shenzhen Aoqi Biopharmaceutical Co., Ltd., a leading talent at the municipal level in Shenzhen, and recipient of the Shenzhen Municipal Government allowance. He has served as the Vice President of a large listed pharmaceutical company and the President of the healthcare division of a well-known domestic private equity firm. He has led the mid-to-long-term strategic planning and R&D execution of multiple pharmaceutical and medical projects, and has been responsible for corporate market capitalization management, investment, financing, and mergers and acquisitions. He has won one national-level science and technology award, two provincial-level science and technology awards in Guangdong, and four municipal-level science and technology awards in Shenzhen. As the first inventor, he holds twelve authorized domestic invention patents and one PCT international patent. Since founding Shenzhen Aoqi Biopharmaceutical Co., Ltd. in 2018 with the dream of "making good medicines accessible," he has led the Aoqi team to develop effective medicines that are affordable for the general public. Aoqi Biopharmaceutical is a company deeply rooted in the pharmaceutical field, providing corporate strategic consulting, project investment incubation, project execution management, and compliance supervision services. To date, Aoqi Biopharmaceutical has launched three products to the market, invested in the development of three new drug projects, provided consulting services to more than ten clients, and offered project management and regulatory services for nearly thirty projects. The company has applied for and owns four patents and two software copyrights.
Former Director of the Shantou Institute for Drug Control in Guangdong Province, National Drug (GMP) Inspector, and Guangdong Province Drug Review Expert.
Former Deputy Minister of GMP at the Shanghai Food and Drug Administration Certification and Evaluation Center, Former Senior GMP Inspector at the National Food and Drug Administration
Liu Weiqiang, Senior Engineer, Former Deputy Minister of the GMP Department at the Certification and Evaluation Center of the Shanghai Food and Drug Administration, Former Senior GMP Inspector of the State Food and Drug Administration,
Has long served as a lecturer for inspector training courses organized by the China Food and Drug Administration and as a mentor for on-site mock inspections.
And served as a trainer for training sessions organized by multiple provincial drug administration bureaus for regulatory personnel and enterprise management staff. Also participated in the revision of certain sections of the 2010 GMP.
Head of Merck Process Solutions Validation Laboratory
Graduated from the Medicinal Chemistry program at Shanghai Jiao Tong University with a master's degree. Has been engaged in sterilizing filtration validation work since 2013, and joined Merck's Shanghai Validation Lab in 2019. Possesses extensive experience in validation testing, project management, and laboratory management related to sterilizing filters, ultrafiltration membrane packs, and single-use systems. Also serves as an internal trainer at Merck, participating in customer training and industry exchanges, primarily teaching validation-related topics in "Regulatory Understanding and Validation of Aseptic Processes and Sterilizing Filtration" and "Single-Use Technology Application Training."
Invited Expert for the 2020 and 2025 Editions of the Chinese Pharmacopoeia (2016Y447, 2022Y29) Pharmaceutical Water Standards System
Zhang Gongchen, a leading talent of the Ministry of Industry and Information Technology (MIIT), has previously worked at China National Pharmaceutical Group. He is a specially invited expert for the 2020 and 2025 editions of the Chinese Pharmacopoeia (Projects 2016Y447 and 2022Y29) under the National Pharmacopoeia Commission’s pharmaceutical water standards system, as well as a specially invited expert on the China National Institutes for Food and Drug Control’s project "Guiding Principles for Microbial Monitoring and Control of Pharmaceutical Water." He serves as an editorial board member for the 2023 edition of the “GMP Guidelines for Pharmaceutical Manufacturing - Premises and Facilities” revision project under the National Medical Products Administration's Inspection Center, specifically for the section on "Pharmaceutical Water Systems." Additionally, he is an editorial board member for the national standard GB 50913, "Design Code for Pharmaceutical Process Water Systems," and the international standard ISO/DIS 22519, "Preparation of Water for Injection by Membrane Filtration." Zhang has led the design and implementation of over 1,200 well-known domestic and international pharmaceutical and healthcare projects. He has authored or co-authored more than 20 professional books in both Chinese and English editions, including the Chinese Pharmacopoeia, GMP Guidelines for Pharmaceuticals, Quality Management Tutorial for Pharmaceutical Production, and Pharmaceutical Water. He also serves as a guest lecturer at Shenyang Pharmaceutical University, Wuhan Institute of Technology, and Shanghai University of Engineering Science.
Former Director of the Microbiology Department at Guangdong Provincial Institute for Drug Control
Long-term engagement in the research of pharmaceutical microbial testing and standard improvement, participating in the addition and revision of microbial-related content in each edition of the Chinese Pharmacopoeia from the 2000 version to the 2025 version.
Chief Expert of Shaanxi Institute for Food and Drug Control
Liu Haijing, First-Class Director Pharmacist (Professional Technical Level II), is an expert who enjoys special allowances from the State Council. She currently serves as the Chief Expert of the Shaanxi Institute for Food and Drug Control, and formerly served as the Party Secretary and President of the same institute. Concurrently, she holds positions such as Chairperson of the Biochemical Pharmaceuticals Committee of the National Pharmacopoeia Commission and Lead Auditor of the Pharmaceutical Committee of the China National Accreditation Service for Conformity Assessment. She has led or participated in more than 10 national and provincial-level scientific research projects; edited or co-edited over 10 monographs; published more than 120 scientific papers; filed 18 national invention patents; and won one first prize and three second prizes of the Shaanxi Provincial Science and Technology Award. She has received honors including "Advanced Worker of Shaanxi Province" and the "Outstanding Achievement Award of the China Pharmaceutical Development Award for Food and Drug Quality Testing."
Former Zhejiang Province Pharmaceutical Supervision Expert, National GMP Inspector
The conference opens several booths:
More on-site booths are being booked fervently, offering diverse promotional and display opportunities for CRO/CDMO/instrument and equipment suppliers/consulting service providers and other enterprises: forum hosting, keynote speeches, venue booths, project roadshows, standing screen displays, conference publication color pages,挂牌, promotional material bags, dinner sponsorship, notebooks, tea break sponsorships, and more.
For more details on business cooperation benefits and fee standards, please inquire:
Ms. Wang 13588474548
Ms. Zhou 15858667450
Ms. Zhang 15005862516
Ms. Cao 15520811395
Ms. Zhou 13983785571
1. Decision-making level personnel such as Chairman and General Manager of pharmaceutical enterprises;
2. R&D, project initiation, clinical directors, managers, researchers, and other personnel in pharmaceutical enterprises;
3. Head of pharmaceutical R&D institution;
4. Head of the clinical trial institution;
5. Person in charge related to MAH B Certificate enterprises;
6. Personnel from drug safety evaluation agencies and drug development consulting organizations;
7. Pharmaceutical company QA/QC/production/registration personnel;
8. Personnel engaged in drug research in pharmaceutical research institutes, drug inspection units, and pharmaceutical higher education institutions;
9. Business BD Leader;
10. Relevant personnel from investment institutions;
Registration: ConferenceFree for a Limited Time(Limited number of participants, first come first served. This registration is a pre-registration. Successful registration will be confirmed after the review is passed!) Accommodation and meals are at your own expense.
Registration Consultation for Participation:
Ms. Cui 13018913819 (Same for WeChat)
Mr. Qi 17280026948 (Same number on WeChat)
Ms. Wen 18868801402 (Same for WeChat)
